Dybly develops pharmaceutical products for patients affected by inflammatory and fibrotic diseases. Our scientific results demonstrate activity in the following pathways: BET-Bromodomain (inhibition); Apo A1 (upregulation); Inflammation (downregulation); Fibrosis (downregulation); Blood cancers: MML and AML (suppression of proliferation).
- Website
- Get directions
- Bookmark
- Share
- Report
- prev
- next
Location
Bäumleingasse 18, 4051 Basel
Facts & figures
-
Type of organizationPrivate company
-
Year of foundation2007
-
Number of employees in Switzerland1-9